322 related articles for article (PubMed ID: 28799202)
21. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
[TBL] [Abstract][Full Text] [Related]
22. Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice.
Gao C; Schroeder JA; Xue F; Jing W; Cai Y; Scheck A; Subramaniam S; Rao S; Weiler H; Czechowicz A; Shi Q
Blood Adv; 2019 Sep; 3(18):2700-2711. PubMed ID: 31515232
[TBL] [Abstract][Full Text] [Related]
23. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Chuah M; VandenDriessche T; Miao CH; Hough C; Lillicrap D
Blood; 2009 Jul; 114(3):677-85. PubMed ID: 19458355
[TBL] [Abstract][Full Text] [Related]
24. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
Lei TC; Scott DW
Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
[TBL] [Abstract][Full Text] [Related]
25. Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.
Chen Y; Schroeder JA; Kuether EL; Zhang G; Shi Q
Mol Ther; 2014 Jan; 22(1):169-77. PubMed ID: 24042561
[TBL] [Abstract][Full Text] [Related]
26. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
27. Reprogrammed CD4
Herzog RW; Kuteyeva V; Saboungi R; Terhorst C; Biswas M
Front Immunol; 2019; 10():274. PubMed ID: 30842776
[TBL] [Abstract][Full Text] [Related]
28. Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells.
Zhang AH; Yoon J; Kim YC; Scott DW
J Immunol; 2018 Sep; 201(5):1434-1441. PubMed ID: 30021767
[TBL] [Abstract][Full Text] [Related]
29. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.
Merlin S; Cannizzo ES; Borroni E; Bruscaggin V; Schinco P; Tulalamba W; Chuah MK; Arruda VR; VandenDriessche T; Prat M; Valente G; Follenzi A
Mol Ther; 2017 Aug; 25(8):1815-1830. PubMed ID: 28552407
[TBL] [Abstract][Full Text] [Related]
30. Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice.
Ramakrishnan R; Davidowitz A; Balu-Iyer SV
J Pharm Sci; 2015 Aug; 104(8):2451-6. PubMed ID: 26038127
[TBL] [Abstract][Full Text] [Related]
31. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
[TBL] [Abstract][Full Text] [Related]
32. Correction of murine hemophilia A by hematopoietic stem cell gene therapy.
Moayeri M; Hawley TS; Hawley RG
Mol Ther; 2005 Dec; 12(6):1034-42. PubMed ID: 16226058
[TBL] [Abstract][Full Text] [Related]
33. Suppression of FVIII-Specific Memory B Cells by Chimeric BAR Receptor-Engineered Natural Regulatory T Cells.
Pohl AP; Venkatesha SH; Zhang AH; Scott DW
Front Immunol; 2020; 11():693. PubMed ID: 32373126
[TBL] [Abstract][Full Text] [Related]
34. Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells.
Miao CH
Expert Rev Hematol; 2010 Aug; 3(4):469-83. PubMed ID: 20976115
[TBL] [Abstract][Full Text] [Related]
35. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A.
Evans GL; Morgan RA
Proc Natl Acad Sci U S A; 1998 May; 95(10):5734-9. PubMed ID: 9576953
[TBL] [Abstract][Full Text] [Related]
36. Donor antigen-primed regulatory T cells permit liver regeneration and phenotype correction in hemophilia A mouse by allogeneic bone marrow stem cells.
Kochat V; Kanjirakkuzhiyil S; Baligar P; Nagarajan P; Mukhopadhyay A
Stem Cell Res Ther; 2015 Jul; 6(1):129. PubMed ID: 26152192
[TBL] [Abstract][Full Text] [Related]
37. The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression.
Shi Q; Mattson JG; Fahs SA; Geurts AM; Weiler H; Montgomery RR
Blood Adv; 2020 Jan; 4(1):55-65. PubMed ID: 31899798
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
39. Platelet-targeted gene therapy induces immune tolerance in hemophilia and beyond.
Kumar S; Schroeder JA; Shi Q
J Thromb Haemost; 2024 Jan; 22(1):23-34. PubMed ID: 37558132
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
